Decentralized Clinical Trials: Evolving Post-Pandemic

By Laura McWhinney, Market Research Manager, ISR

Decentralized clinical trials (DCTs) are studies of some or all trial-related activities conducted at a location separate from the investigators’ primary site. The style of DCTs are reported to have numerous benefits, including convenience and flexibility for patients, greater opportunities for patient recruitment, increased patient diversity, and the potential to decrease timelines and cost. However, as the necessity that drove DCT use (i.e., the COVID-19 pandemic) wanes, the industry is now looking at how biopharmaceutical sponsors’ opinions of DCTs — their utility, affordability, etc. — have evolved as a result.

In ISR’s Decentralized Clinical Trials Market Outlook market research report, data was collected from 114 individuals whose biopharma companies had leveraged DCTs within the last year. Get insight from their responses regarding the overall use of decentralized trials, challenges, areas of investment, eTechnology tool adoption rates, cost predictions, and the future of DCTs.